Bayer's Precision Push: From Field-Level Fungicide Forecasts to a First-in-Class Stroke Drug
Published on 11/12/2026 at 11:01 | Editorial boerse-global.de
Bayer has spent the past week stacking up product news on two fronts that rarely share a headline. On 5 November the group unveiled PrediView, a digital crop-protection concept for winter wheat, and a day earlier it secured Chinese approval for Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer. Sandwiched between them came the US green light for Asundexian, marketed as Sunharbo, to cut the risk of further strokes when combined with an antiplatelet agent. Bayer bills it as the world's first approved factor XIa inhibitor.
What ties the trio together is a shared instinct for narrowing the target. PrediView, due for the 2027 season, pairs field-specific forecasts with a matched fungicide strategy, so that digital information feeds straight into the choice of crop treatment. The two drugs work the same way in clinical terms, homing in on defined patient groups and treatment goals.
A de-risked pipeline, priced cautiously
Jefferies kept Bayer at "Hold" with a price target of 48.50 euros, according to media reports. Analyst Michael Leuchten called the US approval of Asundexian an expected event, adding that the risk to the pharma pipeline had fallen substantially as a result. Deutsche Bank Research took a more bullish line, lifting its target to 65 euros from 60 and reaffirming its buy recommendation, citing the strength of the pharmaceuticals division and higher profit estimates.
The clinical case behind Sunharbo rests on the Phase III OCEANIC-STROKE trial, in which the active ingredient cut ischaemic strokes by 26 percent, according to Bayer, while rates of severe bleeding stayed at a comparable level. That approval was the concrete trigger behind the pickup in demand for Bayer shares at the time.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance raised twice over
The product flow has landed alongside a firming financial picture. Bayer improved its full-year outlook with quarterly figures on 3 November, and Reuters attributed the share-price gain at the time to the raised profit guidance and a better-than-expected performance in pharmaceuticals. For 2026 adjusted operating earnings, the group now expects 9.8–10.3 billion euros, up from a previous range of 9.6–10.1 billion euros. The forecast for the Pharmaceuticals EBITDA margin was lifted to 25 to 27 percent.
Third-quarter 2026 group revenue reached 10.053 billion euros, with EBITDA before special items at 1.615 billion euros — both higher year on year. Last week's upgrade also covered the group EBITDA before special items and free cash flow, and management held out the prospect of lower net financial debt by year-end.
Where the two stories meet
The differing stages of development deserve attention. PrediView is announced for a future season, while both medicines already carry approvals. That gap matters: the value of a defined application area still has to prove itself at the next commercial step.
Bayer at a turning point? This analysis reveals what investors need to know now.
For investors, the test is whether Bayer can convert these narrower applications into durable business that underpins the raised financial ambitions. Higher earnings targets and an improved expected cash inflow give the product narrative a financial floor. Execution on the operating side remains the yardstick — and the connection holds only as long as the progress shows up in earnings and cash flow.
Ad
Bayer Stock: New Analysis - 12 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
